AU587190B2 - Novel galenical retard form - Google Patents

Novel galenical retard form

Info

Publication number
AU587190B2
AU587190B2 AU43486/85A AU4348685A AU587190B2 AU 587190 B2 AU587190 B2 AU 587190B2 AU 43486/85 A AU43486/85 A AU 43486/85A AU 4348685 A AU4348685 A AU 4348685A AU 587190 B2 AU587190 B2 AU 587190B2
Authority
AU
Australia
Prior art keywords
retard form
novel galenical
galenical
novel
retard
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU43486/85A
Other versions
AU4348685A (en
Inventor
Hans Peter Bier
Wolfgang Czarnecki
Jean Claude Gfeller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of AU4348685A publication Critical patent/AU4348685A/en
Application granted granted Critical
Publication of AU587190B2 publication Critical patent/AU587190B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU43486/85A 1984-06-14 1985-06-12 Novel galenical retard form Ceased AU587190B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE3422083 1984-06-14
DE3422083 1984-06-14
DE3442566 1984-11-22
DE3442566 1984-11-22

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU44543/89A Division AU4454389A (en) 1984-06-14 1989-11-09 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
AU4348685A AU4348685A (en) 1985-12-19
AU587190B2 true AU587190B2 (en) 1989-08-10

Family

ID=25822108

Family Applications (2)

Application Number Title Priority Date Filing Date
AU43486/85A Ceased AU587190B2 (en) 1984-06-14 1985-06-12 Novel galenical retard form
AU44543/89A Abandoned AU4454389A (en) 1984-06-14 1989-11-09 Pharmaceutical composition

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU44543/89A Abandoned AU4454389A (en) 1984-06-14 1989-11-09 Pharmaceutical composition

Country Status (21)

Country Link
AT (1) AT391806B (en)
AU (2) AU587190B2 (en)
BE (1) BE902626A (en)
CA (1) CA1264441A (en)
CY (1) CY1635A (en)
DE (1) DE3520184C2 (en)
DK (1) DK167649B1 (en)
ES (1) ES8702141A1 (en)
FR (1) FR2565822B1 (en)
GB (3) GB2160100B (en)
GR (1) GR851430B (en)
HK (1) HK25192A (en)
HU (1) HU198844B (en)
IE (1) IE58834B1 (en)
IL (1) IL75490A0 (en)
IT (1) IT1200080B (en)
LU (1) LU85946A1 (en)
NL (1) NL194389C (en)
NZ (1) NZ212390A (en)
PT (1) PT80635B (en)
SE (1) SE504583C2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1187751B (en) * 1985-10-15 1987-12-23 Eurand Spa PROCEDURE FOR THE PREPARATION OF SOLID FORMULATIONS OF NIFEDIPINE WITH HIGH BIO AVAILABILITY AND WITH PROLONGED EFFECT AND FORMULATIONS SO OBTAINED
US4816263A (en) * 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine
EP0406315B1 (en) * 1988-03-24 1992-11-11 Bukh Meditec A/S Controlled release composition
GR1000270B (en) * 1988-09-30 1992-05-12 Alza Corp Dose for cardiovascular troubles therapy
DK469989D0 (en) * 1989-09-22 1989-09-22 Bukh Meditec PHARMACEUTICAL PREPARATION
MX9300110A (en) * 1992-01-13 1994-07-29 Gerhard Gergely PHARMACEUTICAL PREPARATION IN THE FORM OF AN EFFERVESCENCE OR DISINTEGRATION TABLET OR OF AN INSTANT-TYPE GRANULATE AND PROCEDURE FOR ITS PREPARATION.
DE4201179A1 (en) * 1992-01-17 1993-07-22 Alfatec Pharma Gmbh Granulates or pellets comprising dispersion of active agent in hydrophilic macromolecules - are e.g. for treatment of depression, hypertension, rheumatism, etc.
US6726930B1 (en) 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
GB2281697A (en) * 1993-09-14 1995-03-15 Euro Celtique Sa Laxative compositions in capsules
DE69739165D1 (en) 1996-07-08 2009-01-29 Penwest Pharmaceuticals Co MATRIX WITH DELAYED RELEASE FOR HIGHLY DOSED INSULATED MEDICAMENTS
DE19710009A1 (en) * 1997-03-12 1998-09-24 Knoll Ag Multi-phase preparation forms containing active ingredients
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6787157B1 (en) 1998-03-10 2004-09-07 Abbott Laboratories Multiphase active ingredient-containing formulations
WO2000076480A2 (en) * 1999-06-11 2000-12-21 Eli Lilly And Company Pharmaceutical materials and methods for their preparation and use
US7001892B1 (en) 1999-06-11 2006-02-21 Purdue Research Foundation Pharmaceutical materials and methods for their preparation and use
KR100507400B1 (en) * 1999-08-04 2005-08-10 아스텔라스세이야쿠 가부시키가이샤 Stable medicinal compositions for oral use
CA2352211C (en) 1999-09-30 2009-03-24 Edward Mendell Co., Inc. Sustained release matrix systems for highly soluble drugs
NZ526993A (en) * 2001-02-13 2005-01-28 Astrazeneca Ab Pharmaceutical formulation of a drug substance that has a pH-dependent solubility in water
US7135436B2 (en) 2003-05-05 2006-11-14 J.F. Daley International, Ltd. Solid algicide, preparation and usage in recirculating water
EP1690528A1 (en) 2005-02-11 2006-08-16 Abbott GmbH & Co. KG Process for the preparation of dosage forms comprising a solid dispersion of a microcrystalline active agent
US8399007B2 (en) 2006-12-05 2013-03-19 Landec Corporation Method for formulating a controlled-release pharmaceutical formulation
EP2500015A1 (en) 2006-12-05 2012-09-19 Landec Corporation Delivery of drugs
US8114883B2 (en) 2007-12-04 2012-02-14 Landec Corporation Polymer formulations for delivery of bioactive materials
WO2010022193A2 (en) 2008-08-20 2010-02-25 Board Of Regents, The University Of Texas System Hot-melt extrusion of modified release multi-particulates

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1617362A1 (en) * 1967-11-17 1971-03-25 Beiersdorf Ag Process for the production of medicaments with delayed release of active substances in the form of capsules
DE2400819C2 (en) * 1974-01-09 1982-04-22 Bayer Ag, 5090 Leverkusen Process for the production of solid preparations of poorly soluble active pharmaceutical ingredients in extremely fine distribution
DE2546577B2 (en) * 1975-10-17 1981-04-02 Sandoz-Patent-GmbH, 7850 Lörrach Solid substances made from polyvinylpyrrolidone and ergot alkaloids
GB1504553A (en) * 1975-11-17 1978-03-22 Sandoz Ltd Tablet formulations
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
CH639659A5 (en) * 1978-12-18 1983-11-30 Sandoz Ag NEW 1,4-DIHYDROPYRIDINE DERIVATIVES, THEIR PRODUCTION AND USE.
FI64938C (en) * 1977-06-20 1984-02-10 Sandoz Ag PROCEDURE FOR THE FRAMEWORK OF THERAPEUTIC THERAPEUTIC BENSOX A- AND OX BENZOTIADIAZOLYL-1,4-DIHYDROPYRID DERIVATIVES
EP0001247A1 (en) * 1977-09-14 1979-04-04 Kanebo, Ltd. Pharmaceutical preparation containing nifedipine and a method for producing the same.
FI793888A (en) * 1978-12-21 1980-06-22 Sandoz Ag GALENISKA BLANDNINGAR
DE2904310A1 (en) * 1979-02-05 1980-08-07 Boehringer Mannheim Gmbh MOLDINGS WITH RETARDED ACTIVE SUBSTANCE RELEASE AND METHOD FOR THE PRODUCTION THEREOF
JPS56115726A (en) * 1980-02-20 1981-09-11 Kaken Pharmaceut Co Ltd Pharmaceutical containing nifedipine
DE3033919A1 (en) * 1980-09-09 1982-04-22 Bayer Ag, 5090 Leverkusen SOLID PHARMACEUTICAL PREPARATIONS CONTAINING NIFEDIPINE AND METHOD FOR THE PRODUCTION THEREOF
US4442112A (en) * 1981-09-02 1984-04-10 Sandoz Ltd. Dihydropyridine derivatives useful in treating vascular headaches
EP0078430B2 (en) * 1981-10-29 1993-02-10 Bayer Ag Process for preparing solid fast-releasing drug formulations of dihydropyridines
CA1208558A (en) * 1982-10-07 1986-07-29 Kazuo Kigasawa Soft buccal
DE3318649A1 (en) * 1983-05-21 1984-11-22 Bayer Ag, 5090 Leverkusen TWO-PHASE FORMULATION

Also Published As

Publication number Publication date
GB8514855D0 (en) 1985-07-17
HU198844B (en) 1989-12-28
GB2196851A (en) 1988-05-11
GB2196851B (en) 1989-06-07
AU4454389A (en) 1990-03-22
IT8548210A0 (en) 1985-06-13
IL75490A0 (en) 1985-10-31
BE902626A (en) 1985-12-10
IE58834B1 (en) 1993-11-17
GB8727055D0 (en) 1987-12-23
DK167649B1 (en) 1993-12-06
PT80635B (en) 1987-10-20
NL194389C (en) 2002-03-04
DE3520184A1 (en) 1985-12-19
GB2196852A (en) 1988-05-11
IE851460L (en) 1985-12-14
HUT40918A (en) 1987-03-30
FR2565822B1 (en) 1989-02-17
GB8727056D0 (en) 1987-12-23
ATA174885A (en) 1990-06-15
ES544075A0 (en) 1987-01-01
IT1200080B (en) 1989-01-05
DK264785D0 (en) 1985-06-12
ES8702141A1 (en) 1987-01-01
NL8501578A (en) 1986-01-02
SE504583C2 (en) 1997-03-10
AU4348685A (en) 1985-12-19
NL194389B (en) 2001-11-01
DE3520184C2 (en) 1997-03-13
LU85946A1 (en) 1986-01-24
NZ212390A (en) 1992-02-25
AT391806B (en) 1990-12-10
SE8502950D0 (en) 1985-06-13
GB2160100A (en) 1985-12-18
FR2565822A1 (en) 1985-12-20
CY1635A (en) 1992-11-06
PT80635A (en) 1985-07-01
DK264785A (en) 1985-12-15
GB2160100B (en) 1989-06-01
GR851430B (en) 1985-11-25
HK25192A (en) 1992-04-10
SE8502950L (en) 1985-12-15
GB2196852B (en) 1989-05-17
CA1264441A (en) 1990-01-16

Similar Documents

Publication Publication Date Title
AU587190B2 (en) Novel galenical retard form
AU1117788A (en) Benzoxazone derivatives
AU4982185A (en) Novel 5-amino-4-hydroxyvaleryl derivatives
AU4325485A (en) Aminoalkylphenoxy derivatives
AU4263685A (en) Ammotetralin derivatives
AU5123285A (en) 2-piperizino-pteridine derivatives
AU584104B2 (en) Novel isoindolinyl-alkyl-piperazines
AU4738185A (en) Carbamoylimidazole derivatives
AU4086885A (en) Hydroxy-4-2h-1-benzothiopyran-2-one derivatives
AU4343885A (en) Indole - tetrahydropyridyl derivatives
AU590229B2 (en) Novel homopropargylamines
AU3797485A (en) Azolyl-aryl-alkanol derivatives
AU552800B2 (en) Safe
AU4168885A (en) Chartreusin derivatives
AU4145285A (en) Tetrahydroquinolin-1-yl- carbonylimidazole derivatives
AU4005885A (en) 2-oxindole-1-carboxamide derivatives
AU4901285A (en) 2 - cyanobenzimidazole derivatives
AU4106085A (en) 2 - oxoindole derivatives
AU4045585A (en) Sulphamoylguanidine derivatives
AU3977285A (en) Carboxyalkyldipeptide derivatives
AU4083185A (en) Eburnane derivatives
AU4085185A (en) 1-ph-3-sulfinyl-indole derivatives
AU4594285A (en) Aminoalkylpenem derivatives
AU4045485A (en) Thiatriazine derivatives
SG15492G (en) Novel galenical retard form